8-K current report · filed Oct 29, 2026

ENANTA PHARMACEUTICALS INC (ENTA) 8-K Current Report: October 29, 2026

Item 8.01ENTA overview

Short answer

ENANTA PHARMACEUTICALS INC (ENTA) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 8.01 (Other Events). UPC invalidated Enanta’s EP 4 051 265 patent covering Pfizer’s Paxlovid activities.

ENANTA PHARMACEUTICALS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • UPC invalidated Enanta’s EP 4 051 265 patent covering Pfizer’s Paxlovid activities
  • Infringement claims against Pfizer were dismissed as unfounded across 18 participating EU member states
  • Decision removes this litigation pathway for potential Paxlovid-related remedies or licensing value
  • Pfizer’s counterclaim succeeded, weakening Enanta’s intellectual-property position in Europe

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ENANTA PHARMACEUTICALS INC 8-K filings

Get the next ENTA 8-K as it lands

Follow ENTA for push alerts, or ask the research agent what this filing means.